Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

Sanofi, GSK Pursue COVID-19 Vaccine Trials with $2.1B from “Warp Speed”

GEN - Genetic Engineering and Biotechnology News - Sanofi and GlaxoSmithKline (GSK) will be awarded up to $2.1 billion by the U.S. Departments of Health and Human Services (HHS) and Defense (DoD) toward development and manufacturing of the recombinant protein-based COVID-19 vaccine being produced by the companies.

Read the full article here

Related Content